Updates are available Correction dated 2023-03-14
Click to view Correction: https://doi.org/10.1186/s13023-023-02647-z
-
Authors
Diaz, George A. https://orcid.org/0000-0001-5688-9062
Giugliani, Roberto
Guffon, Nathalie
Jones, Simon A.
Mengel, Eugen
Scarpa, Maurizio
Witters, Peter
Yarramaneni, Abhimanyu
Li, Jing
Armstrong, Nicole M.
Kim, Yong
Ortemann-Renon, Catherine
Kumar, Monica
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 27 June 2022
Accepted: 22 November 2022
First Online: 14 December 2022
Change Date: 14 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-023-02647-z
Declarations
:
: Local Institutional Review Boards (IRB) at all study sites approved the protocol (corresponding author’s IRB: Mount Sinai School of Medicine Program for the Protection of Human Subjects1425 Madison Avenue, East Building 4-78, Box 1075 New York, New York 10029) and patients/parents provided written informed consent prior to patient screening. All clinical data were de-identified. The study adhered to the principles set out in the Declaration of Helsinki.
: Not applicable.
: GAD, SAJ, MS, K. EM, RG, PW, and NG are principal investigators in Sanofi sponsored trials. GAD and SAJ have received honoraria and consulting fees from Sanofi. EM has received research support, honoraria, and consulting fees from Sanofi. RG has received honoraria, consulting fees, speaker fees and travel reimbursement from Sanofi. NG has received honoraria and travel reimbursement from Sanofi. MS has received honoraria, consulting fees, speaker fees and travel reimbursement from Sanofi. PW has participated in advisory boards and received travel reimbursement from Sanofi. AY, JL, NA, YK, CO-R, and MK are employed by Sanofi and may own Sanofi stock.
